Posted on April 10, 2018 by Sitemaster
About 25 years ago the addition of the combination of mitoxantrone + prednisone to androgen deprivation therapy (ADT) was the first form of chemotherapy ever approved for the treatment of metastatic, castration-resistant prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: "high risk", ADT, androgen, deprivation, mitoxantrone, outcome, prednisone, survival | 3 Comments »
Posted on March 20, 2018 by Sitemaster
Last week, we saw that escalated dose did not improve 10-year overall survival in high-risk men (see this link). The latest published findings of the randomized clinical trial (RTOG 0126) prove that 8-year overall survival was not improved in intermediate-risk men who received a higher radiation dose. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: intermediate, outcome, radiation, risk, survival, therapy | 3 Comments »
Posted on March 6, 2018 by Sitemaster
We have previously had no really accurate data on a very important question: Does local treatment of men initially diagnosed with advanced prostate cancer impact their long-term survival and mortality rates? … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: advanced, debulking, outcome, survival, tumor | 4 Comments »
Posted on January 12, 2018 by Sitemaster
For many years now, people have asked whether specific PSA levels after initiation of androgen deprivation therapy (ADT, also known as “hormone therapy”) have significant predictive impact on long-term survival. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, CHAARTED, deprivation, hormone-sensitive, metastatic, PSA, survival | 7 Comments »
Posted on November 16, 2017 by Sitemaster
A newly published study entitled “Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study” is important … but needs to be interpreted with a significant degree of caution. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: cancer-specific, metastatic, mortality, overall, survival, Treatment | 3 Comments »
Posted on November 2, 2017 by Sitemaster
According to a news release just issued by Queen’s University, Belfast, a group of 150 researchers around the world is coming together to expand enrollment and access to the Australian INTERVAL trial into a global trial to test whether serious exercise should be prescribed as part of the treatment for men with advanced prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: exercise, high-intensity, interval, survival, trial | 4 Comments »
Posted on October 26, 2017 by Sitemaster
The first randomized clinical trial to prove that brachy boost radiotherapy had better oncological outcomes among high-risk patients was the one published by Sathya et al. in 2005. … READ MORE …
Filed under: Diagnosis, Management, Treatment | Tagged: boost, brachy, high, intermediate, outcome, radiation, risk, survival | 6 Comments »
Posted on October 17, 2017 by Sitemaster
We have enthusiastically reported the encouraging outcomes of the early clinical trials of the radiopharmaceutical Lu-177-PSMA, most recently at this link. Based on reduction in PSA levels, it performs well. But medicines have no real benefit if all they do is treat PSA. We want medicines that increase survival. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, lutetium-177, mCRPC, metastatic, outcome, PSMA, survival | 8 Comments »
Posted on September 13, 2017 by Sitemaster
Three months ago, James et al. presented the overall survival data from the most recently completed arm of the STAMPEDE trial at the annual meeting of the American Society of Clinical Oncology (ASCO). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: abirtaerone, ADT, hormone-sensitive, locally advanced, node-negative, node-positive, non-metastatic, outcome, STAMPEDE, survival | 7 Comments »
Posted on August 25, 2017 by Sitemaster
A recent data analysis for the Danish national health registry systems has once again provided confirmation of a link between statin use and risk of prostate cancer-specific mortality. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: Diagnosis, mortality, rate, statin, survival, therapy | 3 Comments »
Posted on August 11, 2017 by Sitemaster
As many readers will have realized, the major regulatory authorities started, some time ago, to accept prostate cancer progression-free survival of differing types as a surrogate for overall survival in the approval of some drugs for the treatment of prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: enpoint, metastasis-free, overall, surrogate, survival, trial | 2 Comments »
Posted on August 10, 2017 by Sitemaster
Some 15 months ago, we reported the initial, primary results of the TOAD trial, which showed an overall survival benefit for immediate as opposed to delayed initiation of androgen deprivation therapy (ADT) in non-metastatic patients considered to be inappropriate for curative therapy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, delayed, deprivation, immediate, quality of life, survival, TOAD | 6 Comments »
Posted on June 3, 2017 by Sitemaster
The abstracts of the LATITUDE trial and the comparable arm of the STAMPEDE trial, in which patients with newly diagnosed, metastatic prostate cancer were randomized to either ADT or ADT + abiraterone acetate + prednisone were both released this morning. Both trials have shown major benefits to the early addition of abiraterone acetate to standard care. We shall be providing more details in separate reports to come later today.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: abiraterone, metastatic, survival | Leave a comment »
Posted on March 28, 2017 by Sitemaster
According to new data reported at the annual meeting of the European Association of Urology in London, active surveillance of men diagnosed with low-risk prostate cancer was not associated with an elevated risk for metastatic disease at 15 years of follow-up. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active, follow-up, metastasis, outcome, surveillance, survival | 8 Comments »
Posted on March 16, 2017 by Sitemaster
Several randomized clinical trials have established the superior oncological outcomes of the combination of external beam radiotherapy with a high-dose-rate brachytherapy boost (see this link). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: boost, brachytherapy, high, intermediate, progression-free, risk, survival | 1 Comment »
THE "NEW" PROSTATE CANCER INFOLINK 